MA52238A - Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées - Google Patents

Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées

Info

Publication number
MA52238A
MA52238A MA052238A MA52238A MA52238A MA 52238 A MA52238 A MA 52238A MA 052238 A MA052238 A MA 052238A MA 52238 A MA52238 A MA 52238A MA 52238 A MA52238 A MA 52238A
Authority
MA
Morocco
Prior art keywords
drug conjugates
bonding agents
associated uses
cmet monoclonal
cmet
Prior art date
Application number
MA052238A
Other languages
English (en)
Inventor
Vincent Blot
Julia Coronella
Ryo Fujita
Marco Gymnopoulos
Roland Newman
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MA52238A publication Critical patent/MA52238A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA052238A 2018-03-28 2019-03-27 Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées MA52238A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862649078P 2018-03-28 2018-03-28

Publications (1)

Publication Number Publication Date
MA52238A true MA52238A (fr) 2021-02-17

Family

ID=68059106

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052238A MA52238A (fr) 2018-03-28 2019-03-27 Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées

Country Status (15)

Country Link
US (1) US12060427B2 (fr)
EP (1) EP3774923A4 (fr)
JP (3) JP7177848B2 (fr)
KR (1) KR20200138288A (fr)
CN (1) CN112119098A (fr)
AU (1) AU2019243764A1 (fr)
BR (1) BR112020019465A2 (fr)
CA (1) CA3094827A1 (fr)
IL (1) IL277573A (fr)
MA (1) MA52238A (fr)
MX (1) MX2020010110A (fr)
PH (1) PH12020551556A1 (fr)
SG (1) SG11202009308WA (fr)
TW (1) TWI841555B (fr)
WO (1) WO2019189453A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020180110A (ja) * 2019-03-29 2020-11-05 田辺三菱製薬株式会社 ｃＭＥＴモノクローナル結合剤の薬物複合体を含む医薬組成物
CN111363042B (zh) * 2020-03-30 2022-02-11 中国人民解放军第四军医大学 一种高特异性抗小鼠cd226单克隆抗体及其应用
EP4288456B1 (fr) * 2021-02-03 2024-09-18 Mythic Therapeutics, Inc. Anticorps anti-met et leurs utilisations
CN117157325A (zh) * 2021-04-08 2023-12-01 拜奥迪斯私人有限公司 抗c-met抗体和抗体-药物缀合物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5677426A (en) 1994-03-03 1997-10-14 Genentech, Inc. Anti-IL-8 antibody fragments
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
CA2604805C (fr) 2005-04-21 2014-05-27 Spirogen Limited Pyrrolobenzodiazepines
SG169382A1 (en) * 2006-02-06 2011-03-30 Metheresis Translational Res S A Ch Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
US7910702B2 (en) * 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
CA2716851A1 (fr) 2008-03-06 2009-09-11 Genentech, Inc. Therapie combinee par des antagonistes de c-met et egfr
US8236319B2 (en) 2008-04-30 2012-08-07 Immunogen, Inc. Cross-linkers and their uses
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CN104984360A (zh) 2009-06-03 2015-10-21 伊缪诺金公司 轭合方法
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
US9242013B2 (en) 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
EP2558475A1 (fr) 2010-04-15 2013-02-20 Spirogen Sàrl Pyrrolobenzodiazépines utilisées pour traiter des maladies prolifératives
PL2675479T3 (pl) 2011-02-15 2016-09-30 Cytotoksyczne pochodne benzodiazepiny
JP2014518615A (ja) * 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル， エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
KR101921068B1 (ko) 2011-05-08 2018-11-22 주식회사 레고켐 바이오사이언스 단백질-활성제 접합체 및 이의 제조 방법
KR101860174B1 (ko) 2011-09-20 2018-05-21 메디뮨 리미티드 표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
CN104011018B (zh) 2011-10-14 2016-12-14 麦迪穆有限责任公司 可用于制备吡咯并苯并二氮杂卓的合成方法和中间体
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
EP2750713B1 (fr) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués associés
BR112014009055B1 (pt) 2011-10-14 2021-12-14 Seattle Genetics, Inc. Compostos pirrolobenzodiazepinas, conjugados alvos, ligante de fármaco e uso dos ditos conjugados para tratar uma doença proliferativa
CN110183470A (zh) 2011-10-14 2019-08-30 麦迪穆有限责任公司 吡咯并苯并二氮杂卓
KR101463098B1 (ko) 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
EP2650335B1 (fr) 2012-04-13 2018-05-30 Tata Consultancy Services Ltd. Procédé de synthèse de nanoparticules de dioxyde de titane dopé ayant une activité photocatalytique dans la lumière du soleil
WO2013164593A1 (fr) 2012-04-30 2013-11-07 Spirogen Sàrl Pyrrolobenzodiazépines
WO2013177481A1 (fr) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazépines et leurs conjugués
CA2887896A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Conjugues anticorps anti-her2 - pyrrolobenzodiazepine
CA2885315C (fr) 2012-10-12 2020-06-23 Spirogen Sarl Pyrrolobenzodiazepines et leurs conjugues
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
WO2014062659A2 (fr) * 2012-10-15 2014-04-24 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de maladies oculaires
WO2014080251A1 (fr) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Lieurs hydrophiles et leurs utilisations pour la conjugaison de médicaments à des molécules se liant aux cellules
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2894959C (fr) 2012-12-21 2022-01-11 Spirogen Sarl Dimeres de pyrrolobenzodiazepines asymetriques a utiliser dans le traitement de maladies proliferatives et auto-immunes
HUE043851T2 (hu) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
WO2014174111A1 (fr) 2013-04-26 2014-10-30 Pierre Fabre Medicament Conjugué anticorps anti-axl-médicament et son utilisation pour le traitement du cancer
CA2914189C (fr) 2013-06-21 2023-03-14 Innate Pharma Conjugaison enzymatique de polypeptides
RU2670748C9 (ru) 2013-06-24 2018-12-13 Аблбио Конъюгаты антител с лекарственными агентами, обладающие улучшенной стабильностью, и их применение
KR102150616B1 (ko) 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
AU2014331645C1 (en) 2013-10-11 2020-06-11 Asana Biosciences, Llc Protein-polymer-drug conjugates
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
ES2960619T3 (es) 2014-02-28 2024-03-05 Hangzhou Dac Biotech Co Ltd Enlazadores cargados y sus usos para la conjugación
EP3797793A1 (fr) * 2014-04-18 2021-03-31 The Research Foundation of the State University of New York at Buffalo Anticorps humanisés anti-antigène tf
CA2947238A1 (fr) 2014-05-22 2015-11-26 Synthon Biopharmaceuticals B.V. Medicaments lieurs conjugues en un site specifique a des anticorps et cam resultants
KR102200274B1 (ko) 2014-09-16 2021-01-08 심포젠 에이/에스 항-ｍｅｔ 항체 및 조성물
US20170281796A1 (en) * 2014-12-08 2017-10-05 Sorrento Therapeutics, Inc. c-Met Antibody Drug Conjugate
WO2016149265A1 (fr) 2015-03-16 2016-09-22 Kolltan Pharmaceuticals, Inc. Anticorps anti-met et procédés d'utilisation de ceux-ci
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP4233909A3 (fr) 2016-05-17 2023-09-20 AbbVie Biotherapeutics Inc. Conjugués anticorps-médicament anti-cmet et procédés d'utilisation de ces conjugués
HUE054571T2 (hu) 2016-09-14 2021-09-28 Merck Patent Gmbh Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
WO2018062402A1 (fr) * 2016-09-29 2018-04-05 Mitsubishi Tanabe Pharma Corporation Agents de liaison monoclonaux cmet, leurs conjugués médicamenteux et leurs utilisations

Also Published As

Publication number Publication date
CA3094827A1 (fr) 2019-10-03
MX2020010110A (es) 2020-11-06
US20210163604A1 (en) 2021-06-03
JP7490736B2 (ja) 2024-05-27
TWI841555B (zh) 2024-05-11
JP7177848B2 (ja) 2022-11-24
RU2020135303A (ru) 2022-04-28
CN112119098A (zh) 2020-12-22
JP2024119813A (ja) 2024-09-03
SG11202009308WA (en) 2020-10-29
IL277573A (en) 2020-11-30
WO2019189453A1 (fr) 2019-10-03
PH12020551556A1 (en) 2021-06-07
EP3774923A1 (fr) 2021-02-17
BR112020019465A2 (pt) 2021-01-12
TW201946656A (zh) 2019-12-16
EP3774923A4 (fr) 2021-12-29
US12060427B2 (en) 2024-08-13
AU2019243764A1 (en) 2020-11-05
JP2021519319A (ja) 2021-08-10
JP2023025034A (ja) 2023-02-21
KR20200138288A (ko) 2020-12-09

Similar Documents

Publication Publication Date Title
MA52238A (fr) Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées
MA43859A (fr) Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
MA49990A (fr) Récepteurs de liaison à l'antigène améliorés
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
MA43576A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
EA201890130A1 (ru) Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
MA55868A (fr) Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation
MA49565A (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
MA49846A (fr) Anticorps qui se lient à l'egfr et à cmet
MA53122A (fr) Variants d'anticorps cd38 et leurs utilisations
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
EP3873931A4 (fr) Anticorps anti-cd79b, conjugués anticorps-médicaments et utilisations associées
MA48462A (fr) Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation
PH12016500123A1 (en) Therapeutic fusion protein
MA55818A (fr) Anticorps et immunoconjugués de fr-alpha biparatopique
EP3612567A4 (fr) Anticorps anti-vtcn1 et conjugués anticorps-médicament
MA51147A (fr) Associations d'anticorps anti-c5 et utilisations associées
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
MD3691692T2 (ro) Conjugaţi medicament anticorp activabili anti-CD71 și metode de utilizare a acestora
SG11202109986TA (en) Claudin-6 antibodies and drug conjugates
WO2018111670A3 (fr) Anticorps dirigés contre l'alpha-synucléine humaine
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)